On December 12, 2025, President Trump signed an executive order that sent cannabis stocks surging and industry group inboxes overflowing. The directive, titled “Modernizing the Federal Approach to Cannabis Scheduling,” instructed the Attorney General to “expeditiously initiate proceedings” to evaluate whether cannabis should be moved from Schedule I to Schedule III of the Controlled Substances Act. Within 48 hours, the top ten publicly traded cannabis companies gained a combined $4.2 billion in market capitalization.
Then the DEA issued a clarification, and the air came out of the balloon.
What the Executive Order Actually Says
The executive order does three things. First, it directs the Attorney General to begin or accelerate the administrative rulemaking process for rescheduling cannabis. Second, it establishes a 180-day interagency review of federal cannabis enforcement priorities. Third, it requests that the Department of Health and Human Services provide updated scientific findings on cannabis’s medical applications and abuse potential.
What the executive order does not do is reschedule cannabis. An executive order cannot override the Controlled Substances Act’s procedural requirements. The CSA requires a specific administrative process — HHS scientific review, DEA evaluation, public comment period, and final rulemaking — before any scheduling change takes effect, as detailed in Congressional Research Service reports on cannabis scheduling. The president can direct agencies to start that process or prioritize it, but cannot skip it.
This distinction is not academic. It is the entire ballgame.
The DEA’s January 2026 Clarification
On January 14, 2026, the DEA published a statement confirming what administrative law attorneys had been saying since the executive order dropped: cannabis remains a Schedule I controlled substance, and no scheduling change is effective until the completion of formal rulemaking under the Administrative Procedure Act. For a full history of how cannabis ended up on Schedule I, see our cannabis rescheduling timeline.
The statement noted that the DEA had already initiated a proposed rulemaking in May 2024, following HHS’s August 2023 recommendation, and that an administrative law judge hearing had been completed in late 2025. The executive order, in practice, directed the DEA to do something it was already doing — just louder.
The DEA’s clarification hit cannabis stocks hard. Tilray dropped 18% in a single session. Curaleaf gave back most of its post-executive-order gains. The market learned, again, that the gap between political signaling and regulatory reality is measured in years, not press cycles.
The Administrative Rulemaking Process
The rescheduling process under the CSA is deliberately slow and procedurally rigid. Here is where things stand as of March 2026:
Completed steps: HHS scientific review and recommendation (August 2023). DEA proposed rule published in Federal Register (May 2024). Public comment period with 43,000+ submissions (closed September 2024). Administrative law judge hearing (completed late 2025).
Remaining steps: The ALJ’s recommended decision must be reviewed by the DEA Administrator. A final rule must be drafted, undergo Office of Management and Budget review, and be published in the Federal Register. A 30- to 60-day implementation period follows publication. Legal challenges are virtually guaranteed, though most experts expect the rule to survive judicial review.
Realistic timeline: The final rule is expected between April and August 2026, with an effective date 30 to 60 days later. Even in the most optimistic scenario, no actual scheduling change takes effect before late spring 2026. A more conservative estimate puts the effective date in Q3 or Q4 2026, accounting for litigation stays.
The executive order may have shaved weeks or a few months off this timeline by signaling political support. It did not — and could not — skip any steps.
Rescheduling vs. Descheduling: A Critical Distinction
The cannabis industry’s policy wish list has two very different items on it, and the public conversation frequently conflates them.
Rescheduling to Schedule III means cannabis would join ketamine, testosterone, and Tylenol with codeine as a controlled substance with recognized medical use and moderate abuse potential. Cannabis would still be federally regulated. Manufacturing, distribution, and dispensing would require DEA registration. Prescriptions would be required for legal access, though how this interacts with existing state adult-use markets remains an unresolved legal question that implicates federal preemption concerns.
Descheduling means removing cannabis from the Controlled Substances Act entirely, similar to alcohol and tobacco. This would require an act of Congress. No executive order, DEA rulemaking, or HHS recommendation can deschedule a substance. The STATES Act and various other bills have been introduced to accomplish this, but none have advanced out of committee.
The executive order addresses rescheduling only. Descheduling is not on the administrative table.
What Changes If Rescheduling Happens
The practical impacts of a Schedule III classification are significant but bounded.
280E tax relief. This is the big one. Section 280E of the Internal Revenue Code prohibits businesses trafficking in Schedule I or II substances from deducting ordinary business expenses. Moving cannabis to Schedule III eliminates this restriction, returning an estimated $1.8 billion to $2.4 billion annually to the industry. For individual operators, effective federal tax rates drop from 60-80% to the standard corporate rate of 21%. Multi-state operators like Curaleaf, Green Thumb Industries, and Trulieve have each projected $40 million to $80 million in annual cash flow improvement from 280E relief alone.
Research access. Schedule III dramatically lowers barriers to cannabis research. Investigators would be able to obtain standard DEA research registrations rather than navigating the current Schedule I protocol, which requires additional approval layers and limits source material. University labs could study cannabis with the same procedural framework they use for ketamine studies.
Banking. Schedule III classification would reduce — but not eliminate — banking risk. Cannabis would still be a controlled substance, and financial institutions serving cannabis businesses would still need robust compliance programs. The SAFE Banking Act or similar legislation would still be necessary for full banking normalization. However, the practical risk calculus for banks shifts meaningfully when the substance moves from “no accepted medical use” to “accepted medical use with moderate abuse potential.”
Test your knowledge with our Rescheduling Reality Checker — separating myth from fact on what the executive order actually does.
What Does NOT Change
Even after rescheduling, the following remain true:
State laws still govern. Every state with a legal cannabis program — including states like Virginia, which just launched retail sales — would continue operating under its own regulatory framework. Rescheduling does not create a federal licensing system for recreational cannabis. State licenses, state taxes, and state compliance requirements remain in full effect.
Cannabis is still federally controlled. Possession without a prescription or DEA registration would remain a federal crime under Schedule III. How federal law enforcement approaches state-legal adult-use markets after rescheduling is an open enforcement question.
No interstate commerce. The Controlled Substances Act’s distribution controls would still prohibit moving cannabis across state lines without DEA authorization. The state-by-state market fragmentation that drives up costs and limits competition would persist.
No pharmacy model. Despite Schedule III including drugs available at pharmacies, the existing state dispensary infrastructure would not be displaced. The regulatory transition would be measured in years, not months.
The M&A Wave That Priced In a Fantasy
Perhaps the most telling consequence of the executive order was what happened in the deal market. Within 60 days of the signing, cannabis M&A activity surged past $500 million in announced transactions. Strategic acquirers moved aggressively on distressed operators, using the rescheduling narrative to justify valuations that assumed 280E relief was imminent.
The logic was circular: the executive order made rescheduling feel inevitable, which made cash flow projections look dramatically better, which justified premium acquisition prices — even though the executive order changed nothing about the timeline that was already in motion.
This is the consolidation pattern that has defined cannabis M&A for the past two years: sophisticated operators using narrative momentum to acquire assets at prices that only make sense if federal policy changes on schedule. When the DEA clarification landed, several announced deals quietly saw their terms renegotiated.
The Bottom Line
The December 2025 executive order was a political signal, not a policy change. It accelerated nothing that was not already underway and changed nothing about the legal status of cannabis. The administrative rulemaking process will conclude on roughly the same timeline it would have without the executive order — sometime in mid-to-late 2026.
What the executive order did accomplish was clarifying the current administration’s position: it supports rescheduling and will not use executive authority to obstruct the DEA process. That political cover matters. It reduces the probability that a future Attorney General reverses course, and it signals to institutional investors that the policy direction is durable.
But signals are not statutes. Until the DEA publishes a final rule and that rule survives its inevitable legal challenge, cannabis remains exactly what it has been since 1970: a Schedule I controlled substance with no accepted medical use in the eyes of the federal government. Meanwhile, the upcoming hemp THC ban in the next Farm Bill could further reshape the federal landscape. Every business decision, investment thesis, and compliance framework should be built on that reality — not the press release.